Meningitis vaccination after the Kent outbreak: what families should know
By Dr Daniel Gordon • 18, Mar 2026
Summary Points
The recent Kent outbreak has raised understandable concern, but for most families outside the affected area this is a moment for calm review, not panic.
Many teenagers and young adults are protected against MenACWY, but that vaccine does not protect against MenB.
Most current teenagers and university students will not have received MenB vaccination on the NHS unless they had it privately.
This is a good time to check your own or your child’s vaccination record and make sure you are clear on exactly what has and has not been given.
If MenACWY was missed, catch-up may still be available. If MenB has never been given, private vaccination may be worth discussing.
Vaccination can reduce risk, but it does not prevent every case of meningitis, so it is still important to know the warning signs.
Dear patients and families,
Recent reports of invasive meningococcal disease in Kent have understandably caused concern. At the time of writing, UKHSA has reported 13 notified cases in Kent since 13 March 2026, including 2 deaths. For most families outside the affected area, this is not a reason for panic, but it is a very sensible moment to review vaccination records and make sure you are clear about what protection you or your child have actually had.
If you or your child are in an affected area, or have been contacted by public health teams, you should follow local public health advice, including advice about antibiotics where appropriate.
1) Why this outbreak matters
Meningococcal disease is uncommon, but it can be extremely serious. It is caused by Neisseria meningitidis bacteria and most commonly presents as meningitis, septicaemia, or both. It can progress very quickly, sometimes over hours rather than days, and can lead to severe complications including hearing loss, seizures, limb loss and brain injury. Death can occur within 24 hours of the first symptoms in some cases.
It spreads through respiratory secretions and usually requires frequent or prolonged close contact. Adolescents and young adults are a particularly relevant group because meningococcal bacteria often colonise the back of the nose and throat harmlessly, and risk increases in settings where people mix closely, including university halls and other closed or semi-closed communities.
In practical terms, this is why outbreaks in schools, colleges and universities attract so much attention. Even when the immediate risk to the wider public remains low, these events expose a common problem: many families assume they are “covered” against meningitis without being fully clear which meningitis vaccines they have actually had, and which strains those vaccines do or do not protect against.
In our view, that is the most important reason this outbreak should prompt action.
2) Vaccination in the UK: what is offered and what is not
Meningitis ACWY
In the UK, the MenACWY vaccine is routinely offered to teenagers in school year 9, usually at age 13 to 14. If it was missed at school, catch-up remains available up to age 25. MenACWY protects against four meningococcal groups: A, C, W and Y. It does not protect against MenB.
This is an important point because many young people and parents understandably hear “meningitis vaccine” and assume that means full protection against all major strains. It does not. Even a very effective meningitis vaccine does not prevent all types of meningitis, which is why symptom awareness still matters even in vaccinated people.
Most healthy young people in the UK will only have had one MenACWY dose, and NHS guidance says most people only need one dose. However, antibody protection does decline over time, and other countries, including the United States, use booster strategies more proactively in adolescence and in higher-risk groups.
In our view, that does not mean every healthy teenager in the UK should automatically have a MenACWY booster privately. It does mean that if a MenACWY dose was given over 5 years ago, especially where there is upcoming university exposure, international travel, or a more complex vaccine history, it can be reasonable to discuss whether a further dose is appropriate on an individual basis.
This point is especially relevant for families who have moved between countries. Vaccine schedules vary internationally. A young person vaccinated abroad may have had MenACWY earlier than the UK schedule, may have had a different schedule altogether, or may have gaps that are not obvious until the record is reviewed carefully.
Meningitis B
MenB is different. The MenB vaccine was introduced into the UK infant programme in September 2015. That means most current teenagers and university students will not have received MenB routinely through the NHS unless they were vaccinated privately or because of a specific medical indication. This matters because MenB remains highly relevant in the UK, as we are seeing with the current outbreak.
At the same time, the MenB picture is more nuanced than many people realise. MenB vaccination is not part of a routine NHS catch-up programme for healthy teenagers, and in the United States it is generally handled through shared clinical decision-making for healthy 16 to 23 year olds rather than as a universal programme. The MenB vaccination provides short-term protection, typically around 1 to 2 years, and that therefore the decision to vaccinate should take into account individual circumstances and preferences.
In the UK, a teenager may be fully up to date on the NHS schedule and still never have received MenB vaccination.
In our view, that is not a reason for alarm, but it is a reasonable basis for discussion. If a young person has never had MenB vaccination, particularly if they are approaching sixth form, university, boarding school, travel, or another period of higher social mixing, it is sensible to discuss the pros and cons of private MenB vaccination with a clinician rather than assuming the issue is irrelevant.
For younger children who did receive Bexsero (the Meningitis B vaccine given in the UK) in infancy, the answer is also not completely straightforward. Protection from MenB vaccination is not assumed to remain reliably robust all the way into later adolescence or university, and current UK guidance does not recommend a routine booster for healthy children solely on that basis.
Our view is that families in this position should not make assumptions either way. This is an area that may evolve, so it is worth reviewing the guidance again when a child is older and closer to the age at which their risk profile changes.
Our practical view
Our view at DGA Health is that the most sensible response for families outside the Kent outbreak area is not panic-buying or reactive decision-making. It is to do three things calmly and properly:
check your own or your child’s vaccine history carefully
identify any genuine gaps or uncertainties
discuss with an experienced healthcare professional whether any action is actually appropriate in your circumstances, rather than assuming that one size fits all
In practical terms, that may mean one of the following:
confirming that MenACWY was given
arranging MenACWY catch-up if it was missed
discussing whether an older MenACWY dose warrants review in the context of university, travel, or overseas schedules
discussing whether private MenB vaccination may be reasonable for someone who has never had it
checking that a university-bound young person is also up to date with MMR, not just meningitis vaccines
3) A brief reminder about symptoms
Although this message is mainly about vaccination, it is still important to remember that vaccination does not remove the need to recognise meningitis early. Symptoms can come on quickly, do not always appear in a neat order, and can initially be mistaken for flu or other common illnesses.
Warning signs can include:
high fever
severe headache
vomiting
stiff neck
dislike of bright lights
drowsiness or difficulty waking
confusion
rapid breathing
cold hands and feet
seizures
a rash that does not fade when pressed with a glass
A rash does not always appear, so you should not wait for one before seeking help if someone is becoming significantly unwell. On brown or black skin, the rash can be harder to see, so check paler areas such as the palms, soles, roof of the mouth, tummy, whites of the eyes, or inside the eyelids.
Final note
This message is being shared in good faith as general health information in response to understandable public concern. It is not personalised medical advice and it does not replace an individual consultation with your doctor, your child’s doctor, or paediatrician.
If you or your child are in an affected local area, have been contacted by public health teams, or have symptoms that raise concern for meningitis or septicaemia, you should follow urgent local public health or medical advice rather than relying on general information alone.
For patients and families who would like help reviewing vaccination records or discussing whether MenACWY catch-up, MenACWY review, or private MenB vaccination may be appropriate, DGA Health can offer an individual consultation. Whilst vaccine supply cannot currently be guaranteed (due to UK national shortages), our experienced doctors can offer an individualised discussion and appropriate forward planning for you and your family.
Wishing you only good health
Dr Daniel Gordon & The DGA Health Team
17th March 2026
Disclaimer
This blog post provides general information only. It is not intended to provide instruction and you should not rely on this information to determine a diagnosis, prognosis or course of treatment. It should not be used in place of a professional consultation with a doctor.
The medical information is the personal opinion of the stated author(s). It is based on available evidence or, where no published evidence is available, on current medical opinion and practice.
Every effort is taken to ensure that the information contained in this website is accurate and complete. However, accuracy cannot be guaranteed – rapid advances in medicine may cause information contained here to become outdated, invalid or subject to debate.
The author(s) is/are not responsible for the results of your decisions resulting from the use of the information, including, but not limited to, your choosing to seek or not to seek professional medical care, or from choosing or not choosing specific treatment based on the information.
You should not disregard the advice of your physician or other qualified healthcare provider because of any information you read on this website. If you have any health care questions, please consult a relevant medical practitioner.
